Paediatric Respiratory Reviews
Volume 10, Issue 3 , Pages 118-123 , September 2009

Cystic fibrosis related diabetes

  • Jacquelyn Zirbes
    • ,
  • Carlos E. Milla

      Affiliations

    • Corresponding Author InformationCorresponding author. 770 Welch Rd., Suite 350, MC 5882, Palo Alto, CA 94304, USA. Tel: +1 650 723 5191; Fax: +1 650 723 5201.

References 

  1. Anonymous. The molecular genetic epidemiology of cystic fibrosis. Report of a joint meeting of WHO/ECFTN/ICF(M)/ECFS: Human Genetics Programme, Chronic Diseases and Health Promotion, World Health Organization; 2004.
  2. Kosorok MR, Wei WH, Farrell PM. The incidence of cystic fibrosis. Statistics in Medicine. 1996;15:449–462
  3. Welsh MJ. The path of discovery in understanding the biology of cystic fibrosis and approaches to therapy. American Journal of Gastroenterology. 1994;89:S97–105
  4. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. American Journal of Respiratory & Critical Care Medicine. 1996;154:1229–1256
  5. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. [see comment]. Journal of Pediatrics. 1998;132:589–595
  6. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clinical Reviews in Allergy & Immunology. 2002;23:5–27
  7. Cystic Fibrosis Foundation Patient Registry. 2006 Annual Data Report to the Center Directors Bethesda, MD; 2007 October 2007.
  8. Canadian Cystic Fibrosis Foundation Registry. Canadian Patient Data Registry Report. Toronto, ON; 2002.
  9. UK Cystic Fibrosis Trust. 2004 Annual Data Report. Dundee UK: University of Dundee; 2006.
  10. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Research & Clinical Practice. 1999;45:61–73
  11. Moran A. Diagnosis, screening, and management of cystic fibrosis-related diabetes. Current Diabetes Reports. 2002;2:111–115
  12. Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. Journal of Pediatrics. 1988;112:373–377
  13. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. European Journal of Pediatrics. 1992;151:684–687
  14. Bismuth E, Laborde K, Taupin P, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. Journal of Pediatrics. 2008;152:540–545
  15. Moran A, Milla C. Abnormal glucose tolerance in cystic fibrosis: why should patients be screened?. Journal of Pediatrics. 2003;142:97–99
  16. UK Cystic Fibrosis Trust Diabetes Working Group. Management of cystic fibrosis related diabetes mellitus. UK: Kent; 2004;
  17. De Schepper J, Dab I, Derde MP, Loeb H. Oral glucose tolerance testing in cystic fibrosis: correlations with clinical parameters and glycosylated haemoglobin determinations. European Journal of Pediatrics. 1991;150:403–406
  18. Moreau F, Weiller MA, Rosner V, et al. Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Hormone & Metabolic Research. 2008;40:502–506
  19. Franzese A, Valerio G, Buono P, et al. Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. Journal of Pediatric Endocrinology. 2008;21:109–116
  20. Lohr M, Goertchen P, Nizze H, et al. Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunocytochemical and morphometrical study. Virchows Archiv - A, Pathological Anatomy & Histopathology. 1989;414:179–185
  21. Kopito LE, Shwachman H. The pancreas in cystic fibrosis: chemical composition and comparative morphology. Pediatric Research. 1976;10:742–749
  22. Iannucci A, Mukai K, Johnson D, Burke B. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Human Pathology. 1984;15:278–284
  23. Austin A, Kalhan SC, Orenstein D, Nixon P, Arslanian S. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis. Journal of Clinical Endocrinology & Metabolism. 1994;79:80–85
  24. Cucinotta D, Conti Nibali S, Arrigo T, et al. Beta cell function, peripheral sensitivity to insulin and islet cell autoimmunity in cystic fibrosis patients with normal glucose tolerance. Hormone Research. 1990;34:33–38
  25. Lanng S, Thorsteinsson B, Roder ME, et al. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinologica. 1993;128:207–214
  26. Lippe BM, Sperling MA, Dooley RR. Pancreatic alpha and beta cell functions in cystic fibrosis. Journal of Pediatrics. 1977;90:751–755
  27. Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. Journal of Pediatrics. 1991;118:715–723
  28. Couce M, O’Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. Journal of Clinical Endocrinology & Metabolism. 1996;81:1267–1272
  29. Moran A, Pyzdrowski KL, Weinreb J, et al. Insulin sensitivity in cystic fibrosis. Diabetes. 1994;43:1020–1026
  30. Ahmad T, Nelson R, Taylor R. Insulin sensitivity and metabolic clearance rate of insulin in cystic fibrosis. Metabolism: Clinical & Experimental. 1994;43:163–167
  31. Lanng S, Thorsteinsson B, Roder ME, Nerup J, Koch C. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance. Clinical Endocrinology. 1994;41:217–223
  32. Hardin DS, LeBlanc A, Lukenbough S, Seilheimer DK. Insulin resistance is associated with decreased clinical status in cystic fibrosis. Journal of Pediatrics. 1997;130:948–956
  33. Lombardo F, De Luca F, Rosano M, et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. European Journal of Endocrinology. 2003;149:53–59
  34. Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. [see comment]. Journal of Pediatrics. 1998;133:10–17
  35. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ. 1995;311:655–659
  36. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care. 2005;28:2141–2144
  37. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. Journal of Pediatrics. 2005;146:681–687
  38. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatrica. 1994;83:849–853
  39. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. American Journal of Respiratory & Critical Care Medicine. 2000;162:891–895
  40. Miller M, Ward L, Thomas BJ, Cooksley WG, Shepherd RW. Altered body composition and muscle protein degradation in nutritionally growth-retarded children with cystic fibrosis. American Journal of Clinical Nutrition. 1982;36:492–499
  41. Holt TL, Ward LC, Francis PJ, Isles A, Cooksley WG, Shepherd RW. Whole body protein turnover in malnourished cystic fibrosis patients and its relationship to pulmonary disease. American Journal of Clinical Nutrition. 1985;41:1061–1066
  42. Shepherd RW, Holt TL, Thomas BJ, et al. Nutritional rehabilitation in cystic fibrosis: controlled studies of effects on nutritional growth retardation, body protein turnover, and course of pulmonary disease. Journal of Pediatrics. 1986;109:788–794
  43. Vaisman N, Clarke R, Pencharz PB. Nutritional rehabilitation increases resting energy expenditure without affecting protein turnover in patients with cystic fibrosis. Journal of Pediatric Gastroenterology & Nutrition. 1991;13:383–390
  44. Vaisman N, Clarke R, Rossi M, Goldberg E, Zello GA, Pencharz PB. Protein turnover and resting energy expenditure in patients with undernutrition and chronic lung disease. American Journal of Clinical Nutrition. 1992;55:63–69
  45. Hardin DS, LeBlanc A, Lukenbaugh S, Para L, Seilheimer DK. Proteolysis associated with insulin resistance in cystic fibrosis. Pediatrics. 1998;101:433–437
  46. Moran A, Milla C, Ducret R, Nair KS. Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance. Diabetes. 2001;50:1336–1343
  47. Steinkamp G, von der Hardt H. Improvement of nutritional status and lung function after long-term nocturnal gastrostomy feedings in cystic fibrosis. Journal of Pediatrics. 1994;124:244–249
  48. Shepherd RW, Thomas BJ, Bennett D, Cooksley WG, Ward LC. Changes in body composition and muscle protein degradation during nutritional supplementation in nutritionally growth-retarded children with cystic fibrosis. Journal of Pediatric Gastroenterology & Nutrition. 1983;2:439–446
  49. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF, Dearborn DG. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. American Review of Respiratory Disease. 1985;132:529–535
  50. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. American Journal of Respiratory & Critical Care Medicine. 1994;150:448–454
  51. Meyer KC, Zimmerman J. Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis. Journal of Laboratory & Clinical Medicine. 1993;121:654–661
  52. Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. American Journal of Respiratory & Critical Care Medicine. 1994;150:207–213
  53. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory & Critical Care Medicine. 1995;151:1075–1082
  54. Regelmann WE, Siefferman CM, Herron JM, Elliott GR, Clawson CC, Gray BH. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis. Pediatric Pulmonology. 1995;19:1–9
  55. Wood DM, Brennan AL, Philips BJ, Baker EH. Effect of hyperglycaemia on glucose concentration of human nasal secretions. Clinical Science. 2004;106:527–533
  56. Baker EH, Wood DM, Brennan AL, Clark N, Baines DL, Philips BJ. Hyperglycaemia and pulmonary infection. Proceedings of the Nutrition Society. 2006;65:227–235
  57. Brennan AL, Gyi KM, Wood DM, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. Journal of Cystic Fibrosis. 2007;6:101–109
  58. O’Riordan SMP, Robinson PD, Donaghue KC, Moran A. Consensus ICP. Management of cystic fibrosis-related diabetes. Pediatric Diabetes. 2008;9:338–344
  59. Nair KSFG, Halliday D. Effect of intravenous insulin treatment on in vivo whole body leucine kinetics and oxygen consumption in insulin-deprived type 1 diabetic patients. Metabolism. 1987;36:5
  60. Jefferson LS. Role of insulin in the regulation of protein synthesis. Diabetes. 1980;29:9
  61. Huszar GKV, Davis E, Felig P. Urinary 3-Methylhistidine excretion in juvenile onset diabetes: Evidence of increased protein catabolism in the absence of ketoacidosis. Metabolism. 1982;31:4
  62. Pacy PJNK, Ford C, Halliday D. Failure of insulin to stimulate fractional muscle protein synthesis in type 1 diabetic patients. Diabetes. 1989;38:7
  63. Mohan K, Miller H, Burhan H, Ledson MJ, Walshaw MJ. Management of cystic fibrosis related diabetes: a survey of UK cystic fibrosis centers. Pediatric Pulmonology. 2008;43:642–647
  64. Hinds A, Sheehan AG, Parsons HG. Tolbutamide causes a modest increase in insulin secretion in cystic fibrosis patients with impaired glucose tolerance. Metabolism: Clinical & Experimental. 1995;44:13–18
  65. Zipf WB, Kien CL, Horswill CA, McCoy KS, O’Dorisio T, Pinyerd BL. Effects of tolbutamide on growth and body composition of nondiabetic children with cystic fibrosis. Pediatric Research. 1991;30:309–314
  66. Culler FL, McKean LP, Buchanan CN, Caplan DB, Meacham LR. Glipizide treatment of patients with cystic fibrosis and impaired glucose tolerance. Journal of Pediatric Gastroenterology & Nutrition. 1994;18:375–378
  67. Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treatments in Endocrinology. 2003;2:401–414
  68. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care. 2001;24:1706–1710
  69. Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Archives of Disease in Childhood. 2002;87:430–431
  70. Franzese A, Spagnuolo MI, Sepe A, Valerio G, Mozzillo E, Raia V. Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes? Diabetes Care. 2005;28:2333
  71. Diabetes therapy to imporve BMI and lung function in CF. 2009.(Accessed 2/28/2009, 2009, at http://clinicaltrials.gov/ct2/show/NCT00072904).
  72. Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care. 2006;29:2660–2663
  73. Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care. 2007;30:1056–1061
  74. van den Berg JMMA, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis related diabetes. Journal of Cystic Fibrosis. 2008;7:5

PII: S1526-0542(09)00036-0

doi: 10.1016/j.prrv.2009.04.004

Paediatric Respiratory Reviews
Volume 10, Issue 3 , Pages 118-123 , September 2009

Article Tools

* Image Usage & Resolution